微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 31.36% | -1.62% | -2.17% | 15/159 | 42.2% | 恩华药业 | 71.67% | 行业排名> |
| 2026-06-30 | 32.06% | -0.81% | -0.71% | 109/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 32.29% | -0.23% | 1.68% | 108/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 31.75% | 2.3% | -0.38% | 114/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 31.88% | -0.98% | -1.38% | 112/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 32.32% | -3.4% | -0.13% | 111/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 32.36% | -2.95% | 4.26% | 108/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 31.04% | -2.05% | -3.57% | 119/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 32.19% | 2.17% | -3.79% | 113/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 33.46% | 4.92% | 0.34% | 112/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 33.34% | 2.57% | 5.22% | 109/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 31.69% | 6.44% | 0.59% | 118/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.5% | 7.21% | -1.2% | 115/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 31.89% | 6.06% | -1.92% | 116/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 32.51% | 8.98% | 9.19% | 113/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 29.77% | 3.05% | 1.32% | 120/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.39% | 1.84% | -2.25% | 113/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 30.06% | -0.34% | 0.78% | 116/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 29.83% | -0.7% | 3.25% | 112/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 28.89% | -6.67% | 0.13% | 128/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 28.85% | -7.17% | -4.34% | 115/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 30.16% | -6.81% | 0.42% | 122/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 30.04% | -13.18% | -2.96% | 105/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 30.96% | -15.27% | -0.41% | 124/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 31.08% | -15.28% | -3.98% | 104/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 32.37% | -11.61% | -6.45% | 111/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 34.6% | -0.26% | -5.29% | 90/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 36.53% | 7.72% | -0.43% | 105/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 36.69% | 8.81% | 0.18% | 83/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 36.62% | 10.65% | 5.57% | 85/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 34.69% | 11.61% | 2.28% | 85/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 33.92% | 9.7% | 0.59% | 104/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 33.72% | 8.48% | 1.88% | 81/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 33.1% | 4.71% | 6.49% | 84/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 31.08% | -1.49% | 0.53% | 84/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.92% | -8.54% | -0.54% | 96/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 31.08% | -11.23% | -1.67% | 75/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 31.61% | -12.46% | 0.18% | 76/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 31.55% | -11.07% | -6.66% | 61/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 33.8% | -2.43% | -3.47% | 79/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 35.02% | 1.63% | -3.02% | 53/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 36.11% | 3.98% | 1.77% | 59/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 35.48% | 2% | 2.41% | 51/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |